Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.
Saved in:
| Title: | Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany. |
|---|---|
| Authors: | Basic E; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany. edin.basic@takeda.com., Kappel M; Health Economics, WifOR, Darmstadt, Germany., Misra A; Health Economics, WifOR, Darmstadt, Germany., Sellner L; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany., Ratsch BA; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany., Ostwald DA; Health Economics, WifOR, Darmstadt, Germany.; School of International Business and Entrepreneurship (SIBE), Steinbeis University Berlin, Berlin, Germany. |
| Source: | The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2020 Dec; Vol. 21 (9), pp. 1351-1361. Date of Electronic Publication: 2020 Jul 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1618-7601 |
|---|---|
| DOI: | 10.1007/s10198-020-01219-3 |
